NCT05465512View on ClinicalTrials.gov

Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy

CompletedOBSERVATIONAL

Enrollment

193

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

June 1, 2022

Study Completion Date

July 10, 2022

Conditions

Gastric Cancer

Interventions

OTHER

response to neoadjuvant chemotherapy

Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).

Trial Locations (1)

Unknown

Department of Gastric Surgery, Fuzhou

All Listed Sponsors

lead

Fujian Medical University

OTHER

NCT05465512 - Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy | Biotech Hunter | Biotech Hunter